Clinical-Stage Pharmaceutical Company
A clinical-stage pharmaceutical company developing science-driven pharmaceutical therapies for scalp and eyebrow hair growth.
Issued U.S. patents
U.S. patent claims
Countries with granted patents
Lead Clinical Programs
The Follicle — Our Signature Biology
The Challenge
Androgenetic alopecia is the most common form of hair loss, affecting both men and women. Despite its prevalence, therapeutic innovation has been limited for decades — and satisfaction with existing options remains low.
Global androgenetic alopecia market — estimated 2026
Global androgenetic alopecia market — projected 2030
Androgenetic alopecia market CAGR, 2024–2030
Source: Grand View Research, Androgenetic Alopecia Market Report (2024). Accessed 2026-07. Therapeutic market definition — excludes cosmetics and general hair care.
The Science
Aneira's lead programs combine two established pharmacologies whose mechanisms converge on the biology of the hair follicle.
MINOXIDIL
Convergent
follicular
activation
LATANOPROST
Designed to support terminal hair that is
Lead Programs
Aneira's dual-mechanism platform is being advanced across two highly attractive initial indications.
A once-daily topical fixed-dose combination designed to stimulate hair follicles and increase target-area hair count, diameter, and darkness in both men and women.
Minoxidil + Latanoprost
Clinical-stage — Phase 2a signal reported; larger controlled trials in preparation
Explore ProgramA once-daily topical drop specifically formulated for the eyebrow, designed to increase eyebrow density and fullness.
Minoxidil + Latanoprost
Clinical-stage — early human signal reported; larger controlled trials in preparation
Explore ProgramANR-001.1 and ANR-001.2 are investigational and are not approved for commercial use.
Clinical Evidence
Early clinical signals across both lead programs are directionally consistent with the dual-mechanism hypothesis — and are being advanced into larger controlled trials.
Scalp — ANR-001.1
Early-phase evaluation; results expressed as a relative index normalized to the combination arm (= 100). Duration: 120 days, once-daily application. Investigational. Early-stage data are not a prediction of individual outcomes and are subject to confirmation in larger controlled trials.
Eyebrow — ANR-001.1
Average increase in eyebrow fullness
+54.60%
Day 90 · combination arm (n=8)
Early-phase, vehicle-controlled evaluation with assessments at Day 30, 60 and 90. Sample size: Combination n=8; vehicle n=4. Investigational. Early-stage data are not a prediction of individual outcomes and are subject to confirmation in larger controlled trials.
Selected Observed Responses
Evidence Framework
It is strongly established that the combination of topical Minoxidil and Latanoprost grows hair to a high degree.
Prostaglandin analogues including latanoprost have scientific and clinical precedent supporting effects on hair biology.
Aneira's early human data provide encouraging signals across scalp and eyebrow programs.
Larger controlled clinical studies are intended to define efficacy, optimal formulation, tolerability and safety.
Intellectual Property
A global intellectual-property portfolio designed to protect Aneira's innovation and support long-term development.
Issued U.S. patents*
U.S. patent claims*
Countries with granted patents*
Additional countries pending*
Potential protection horizon*
Of world GDP within filing footprint*
*Subject to verification against the latest Aneira patent schedule before publication.
Explore Our IP
Eyebrow Hypotrichosis — ANR-001.2
Market Context
The current eyebrow growth market is served almost entirely by cosmetic serums. A clinically validated pharmaceutical approach remains an open opportunity.
Eyebrow growth serum market — 2025 estimate
Eyebrow growth serum market — 2032 projection
Broader eyebrow + lash serum category — 2025 estimate
Cosmetic / serum category estimates from public market research (2025). These are distinct market definitions and are never combined.
The Road Ahead
Aneira Pharma is advancing science-driven pharmaceutical therapies toward larger controlled clinical trials — with global intellectual property and two lead programs.
